Immuneering Q2 net loss $12.2M; cash runway extended into 2025; IMM-1-104 Phase 1b enrolling

Immuneering Corp

2023-Q2 EPS reported -$0.94

Net loss of $12.2M ($0.43 per share) vs $11.5M ($0.44 per share) in Q2 2022.
Cash and equivalents $109.0M at June 30, 2023; expects cash runway into 2025.
Completed $30M underwritten offering of 2.73M shares at $11.00 in April 2023.
IMM-1-104 Phase 1a dose escalation completed with no dose-limiting toxicities; Phase 1b enrolling at 240mg or 320mg daily.
RP2D expected early 2024; IND filing for IMM-6-415 expected Q4 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Immuneering Corp reported the second quarter ended June 30, 2023 results: net income $12.2 million, or $0.43 per share, EPS $0.43 per share.

Period: the second quarter ended June 30, 2023
Net income: $12.2 million, or $0.43 per share
EPS: $0.43 per share
Result: reported results

Exact text from the filing

Net loss attributable to common stockholders was $12.2 million, or $0.43 per share, for the quarter ended June 30, 2023, compared to $11.5 million, or $0.44 per share, for the quarter ended June 30, 2022.

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

Immuneering Corp filing history →

Source: SEC EDGAR

accession 0001790340-23-000046

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.